Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475706 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
A Phase 2 study, sponsored by Velicept Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 438
- Enrollment target
NCT03475706: Completed Phase 2 study, sponsored by Velicept Therapeutics.
NCT03475706 is a Phase 2 study that has completed, run by Velicept Therapeutics. The registered enrollment target is 438 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03475706, a Phase 2 study, has completed, sponsored by Velicept Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 438 participants
- Enrollment target
Study Summary
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and predominantly urgency incontinence) for at least 6 months.
Primary Outcome
Micturition events will be recorded by subjects in an eDiary using a smartphone device during 3-day diary periods prior to randomization and at 12 weeks.
Interventions
- DRUG Matching Placebo
- DRUG Solabegron immediate release tablets, low dose
- DRUG Solabegron immediate release tablets, high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 2 |
What the finished NCT03475706 record still lists
NCT03475706 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher).
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT03475706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03475706 about?
NCT03475706 is a clinical study titled "Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women". This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult f...
What is the current status of trial NCT03475706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2018-02-19. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT03475706?
The interventions under investigation include: Matching Placebo (DRUG), Solabegron immediate release tablets, low dose (DRUG), Solabegron immediate release tablets, high dose (DRUG).
Who is sponsoring clinical trial NCT03475706?
This trial is sponsored by Velicept Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03475706's enrollment target sits among peer trials
438 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI